AstraZeneca PLC Chair succession (1646U)
29 Julio 2022 - 1:01AM
UK Regulatory
TIDMAZN
RNS Number : 1646U
AstraZeneca PLC
29 July 2022
29 July 2022 07:01 BST
Michel Demaré to succeed Leif Johansson as
Non-Executive Chair of the Board
AstraZeneca PLC today announced the appointment of Michel Demaré
as the Chair-designate of the Board.
His appointment followed a robust succession planning process
led by Philip Broadley in his capacity as senior independent
Non-Executive Director.
As previously communicated, Leif Johansson, current Chair of the
Board of AstraZeneca will be retiring at the conclusion of the
Company's Annual General Meeting in April 2023. Michel's
appointment will take effect immediately on Leif's retirement
allowing for a managed handover period over the coming months.
Michel was appointed to the Board of AstraZeneca in September
2019 as an independent Non-Executive Director and is currently
Chair of the Company's Remuneration Committee and member of the
Audit Committee and the Nomination and Governance Committee. He is
a Non-Executive Director of Vodafone Group Plc and Louis Dreyfus
Int'l Holdings BV. He is also Chairman of IMD Business School and
Chairman of Nomoko AG.
Leif Johansson, AstraZeneca Chair said: "I am delighted that
Michel will succeed me following the 2023 AGM. He is an
internationally respected leader with extensive experience in
strategy, planning, execution, governance and corporate stewardship
and a proven track record leading multinational companies, as well
as experience of the pharmaceutical industry gained at Baxter and
as a member of the AstraZeneca Board. I look forward to undertaking
a comprehensive handover in the coming months and to seeing the
continued development and success of AstraZeneca."
Michel Demaré, AstraZeneca Chair-designate said: "I could not be
prouder to be named Chair-designate of the Board of AstraZeneca and
am excited to have the opportunity to build on Leif's success as
Chair and work with Pascal and members of the Board and Senior
Executive Team when I take on my new role in 2023."
Notes
Biography and photograph:
https://www.astrazeneca.com/our-company/leadership.html#board
Remuneration:
Effective 1 May 2023, the fee for the Chair of the Board will be
GBP800,000 per annum, paid wholly in cash. The Chair's fee was last
increased in January 2018.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAUWUBRURUBUAR
(END) Dow Jones Newswires
July 29, 2022 02:01 ET (06:01 GMT)
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Astrazeneca (LSE:AZN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024